title: Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
abstract: Some cytochrome P450 catalyzed reactions show atypical kinetics, and these kinetic processes can be grouped into five categories: activation, autoactivation, partial inhibition, substrate inhibition, and biphasic saturation curves. A two-site model in which the enzyme can bind two substrate molecules simultaneously is presented which can be used to describe all of these observed kinetic properties. Sigmoidal kinetic characteristics were observed for carbamazepine metabolism by CYP3A4 and naphthalene metabolism by CYPs 2B6, 2C8, 2C9, and 3A5 as well as dapsone metabolism by CYP2C9. Naphthalene metabolism by CYP3A4 and naproxen metabolism by CYP2C9 demonstrated nonhyperbolic enzyme kinetics suggestive of a low Km, low Vmax component for the first substrate molecule and a high Km, high Vmax component for the second substrate molecule. 7, 8-Benzoflavone activation of phenanthrene metabolism by CYP3A4 and dapsone activation of flurbiprofen and naproxen metabolism by CYP2C9 were also observed. Furthermore, partial inhibition of 7, 8-benzoflavone metabolism by phenanthrene was observed. These results demonstrate that various P450 isoforms may exhibit atypical enzyme kinetics depending on the substrate(s) employed and that these results may be explained by a model which includes simultaneous binding of two substrate molecules in the active site.
authors.affiliation: Center for Clinical Pharmacology, University of Pittsburgh, Pennsylvania 15217, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: Korzekwa
authors.forename: N
authors.initials: N
authors.lastname: Krishnamachary
authors.forename: M
authors.initials: M
authors.lastname: Shou
authors.forename: A
authors.initials: A
authors.lastname: Ogai
authors.forename: R A
authors.initials: RA
authors.lastname: Parise
authors.forename: A E
authors.initials: AE
authors.lastname: Rettie
authors.forename: F J
authors.initials: FJ
authors.lastname: Gonzalez
authors.forename: T S
authors.initials: TS
authors.lastname: Tracy
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases; D001665:Binding Sites; D002220:Carbamazepine / Q000378:metabolism; D065729:Cytochrome P-450 CYP2C9; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000737:chemistry* / Q000378:metabolism*; D003622:Dapsone / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008862:Microsomes, Liver / Q000201:enzymology; D006899:Mixed Function Oxygenases / Q000378:metabolism; D008956:Models, Chemical; D009288:Naproxen / Q000378:metabolism; D011485:Protein Binding; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000378:metabolism; D013379:Substrate Specificity
chemical_list: D002220:Carbamazepine; D009288:Naproxen; D003622:Dapsone; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D013250:Steroid Hydroxylases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D039181:Steroid 16-alpha-Hydroxylase; C510163:CYP3A4 protein, human